PMID- 19968064
OWN - NLM
STAT- MEDLINE
DCOM- 20121119
LR  - 20091208
IS  - 1000-503X (Print)
IS  - 1000-503X (Linking)
VI  - 31
IP  - 5
DP  - 2009 Oct
TI  - [Effects of killer immunoglobulin-like receptor and human leukocyte antigen class 
      I ligand on the prognosis of related donor hematopoietic stem cell 
      transplantation].
PG  - 533-7
AB  - OBJECTIVE: To study the genotype distribution and the effects of killer 
      immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA) class I 
      ligand on related donor hematopoietic stem cell transplantation (HSCT). METHODS: 
      The genotypes of donor/recipient HLA-Cw and donor KIR were determined by 
      polymerase chain reaction-sequence specific primer (PCR-SSP) in 87 cases of 
      related donor HSCT (40 cases were haploidentical HSCT, and the remaining 47 cases 
      were HLA-identical sibling HSCT). RESULTS: All the donors possessed KIR2DL1, 
      2DL2/L3, 2DL4, 3DL2, and 3DL3, and 96.6% of donors possessed 3DL1. The rate of 
      activating KIRs varied. 97.7% of the recipients expressed C1, while the rates of 
      C2, Bw4, and HLA-A3/A11 were different. In haploidentical HSCT, 
      KIR-HLA-mismatched group included 34 cases and the matched group included 6 
      cases. HLA-HLA-mismatched group included 31 cases and the matched group included 
      9 cases. In matched sibling donor HSCT, KIR-HLA-mismatched group included 42 
      cases and the matched group included 5 cases. KIR-HLA-mismatched group had higher 
      2-year disease-free survival (DFS) rate compared with KIR-HLA-matched group [ 
      (71.5 +/- 6.5 ) % vs. (50.0 +/- 10.7)%, P < 0.05]. CONCLUSIONS: The rate of 
      activating KIR is lower than inhibitory KIRs. Inhibitory KIR2DL1, 3DL1, and 3DL2 
      may play key roles in the natural killer cell alloreactivity. The DFS rate is 
      higher in KIR-HLA-mismatched group than in KIR-HLA-matched group in related donor 
      HSCT.
FAU - Wang, Hua
AU  - Wang H
AD  - State Key Laboratory of Experimental Hematology, Institute of Hematology and 
      Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.
FAU - Zhai, Wen-Jing
AU  - Zhai WJ
FAU - Wang, He-Hua
AU  - Wang HH
FAU - He, Yi
AU  - He Y
FAU - Zhou, Zheng
AU  - Zhou Z
FAU - Zhao, Ying-Xin
AU  - Zhao YX
FAU - Zhai, Wei-Hua
AU  - Zhai WH
FAU - Zhang, Rong-Li
AU  - Zhang RL
FAU - Wang, Mei
AU  - Wang M
FAU - Feng, Si-Zhou
AU  - Feng SZ
FAU - Han, Ming-Zhe
AU  - Han MZ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao
JT  - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
JID - 8006230
RN  - 0 (HLA Antigens)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptors, KIR/*genetics
MH  - Young Adult
EDAT- 2009/12/09 06:00
MHDA- 2012/12/10 06:00
CRDT- 2009/12/09 06:00
PHST- 2009/12/09 06:00 [entrez]
PHST- 2009/12/09 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
PST - ppublish
SO  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):533-7.